
Cytokine Therapies: Novel Approaches for Clinical Indications
Thursday, March 26, 2009 - Friday, March 27, 2009
Despite outstanding therapeutic promise and sound scientific rationale, most cytokine therapies have largely failed to establish clinical utility. This meeting is designed as a forum to critically assess the factors that are limiting the clinical development of cytokines as therapeutic agents. It will cover the successes and failures of recombinant cytokines as therapeutic agents for treating human diseases, including various cancers and autoimmune diseases, and will provide a forum to review the scientific and clinical basis of both successful and unsuccessful attempts to develop cytokines as therapeutic agents. The goal is to identify areas for improvement and to coordinate, develop and disseminate novel approaches to current scientific hurdles that are limiting the development of many cytokine products.
Topics for discussion will include:
- Improved methods for identifying disease targets
- Alternative methods for enhancing and targeting cytokine delivery
- Physicochemical modification of cytokines to prolong their bioavailability
Scientific Organizing Committee
- Raymond P. Donnelly, PhD, Food and Drug Administration
- Amy Rosenberg, MD, Food and Drug Administration
- Howard Young, PhD, National Cancer Institute
- Kathy Granger, PhD, The New York Academy of Sciences
Presented by
Presented by
This conference is supported by an educational donation provided by:
Abbott Laboratories
Amgen Inc
Celgene Corporation
Centocor Research and Development, Inc
Sponsors
BioLegend
Invitrogen
PBL InterferonSource
Media Partners
Bristish Pharmacological Society
Journal of Interferon and Cytokine Research
Nature Immunology
The Federation of Clinical Immunology Societies
The International Society for Interferon and Cytokine Research
The Journal of Clinical Investigation
The Lancet